PolySeq key facts
as of Oct 2026- Developer of a nanopore sequencing platform for the purpose of the fourth-generation gene sequencer and supporting reagent consumables.
- PolySeq is valued at approximately $69.5M as of Oct 2026 (last reported valuation).
- It has raised $36.2M; the latest was Early Stage VC ($21.8M) in Mar 2026.
- Notable investors include IDG Capital, Tsinghua Innovation Ventures, BOC Financial Assets Investment, Chang Development, KSCY Holding Group — 9 tracked in total.
- Status: Privately Held (backing).
PolySeq's last reported valuation, May 2023. Nothing priced has surfaced since.
- ·Watch PolySeq: the Monday email on marks, rounds and moves
PolySeq funding rounds
No funding rounds for PolySeq are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
PolySeq valuation
PolySeq's last reported valuation was $69.5 million in May 2023. No priced round, secondary trade or fund mark has surfaced since.
PolySeq investors
9 investors are on record for PolySeq, including IDG Capital, Tsinghua Innovation Ventures, BOC Financial Assets Investment and Chang Development.
About PolySeq
Developer of a nanopore sequencing platform for the purpose of the fourth-generation gene sequencer and supporting reagent consumables. The company's product development is based on the principle of biological nanopore gene sequencing, combined with semiconductor integrated chips, deep learning and genomics technologies, enabling clients to increase the application rate of gene sequencing technology.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- polyseq.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.